ImmunityBio Inc (NASDAQ:IBRX) finished Wednesday with an addition of $0.13 to close at $1.60, an upside of 8.50 percent. An average of 1,943,060 shares of common stock have been traded in the last five days. There was a fall of -$0.0800 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 3,380,845 shares traded, while the 50-day average volume stands at 2,817,034.
IBRX stock has decreased by -3.33% in the last month. The company shares reached their 1-month lowest point of $1.2700 on 09/08/23. With the stock rallying to its 52-week high on 05/09/23, shares of the company touched a low of $1.21 and a high of $7.10 in 52 weeks. It has reached a new high 4 times so far this year and lost -68.54% or -$3.4750 in price. In spite of this, the price is down -77.54% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
ImmunityBio Inc (IBRX) stock’s beta is 1.40. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 1233.42.
Financial Health
The quick ratio of ImmunityBio Inc for the three months ended June 29 was 0.11, and the current ratio was 0.11, indicating that the company is not able to meet its debt obligations. ImmunityBio Inc’s EBITDA margin for the year ending June 29 is -136010.42%, while its operating margin for the same period stands at -62795.27%. Its gross profit as reported stood at $351.54 million compared to revenue of $0.24 million.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$137.88 million in the quarter, while revenues of -$116.34 million were grew 31.4%. The analyst consensus anticipated ImmunityBio Inc’s latest quarter earnings to come in at -$0.23 per share, but it turned out to be -$0.32, a -39.10% surprise. For the quarter, EBITDA amounted to -$68.17 million. Shareholders own equity worth $456.25 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at ImmunityBio Inc (IBRX) price momentum. RSI 9-day as of the close on 27 September was 47.72%, suggesting the stock is Neutral, with historical volatility in this time frame at 100.90%.
As of today, IBRX’s price is $1.5920 -4.78% or -$0.0800 from its 5-day moving average. IBRX is currently trading -2.15% lower than its 20-day SMA and -58.79% lower than its 100-day SMA. However, the stock’s current price level is -46.30% below the SMA50 and -74.32% below the SMA200.
The stochastic %K and %D were 49.71% and 54.98%, respectively, and the average true range (ATR) was 0.1579. With the 14-day stochastic at 56.03% and the average true range at 0.1598, the RSI (14) stands at 46.13%. The stock has reached -0.0967 on the 9-day MACD Oscillator while the 14-day reading was at -0.0663.
Analyst Ratings
Piper Sandler downgraded ImmunityBio Inc (NASDAQ: IBRX) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as an Overweight. The consensus rating for ImmunityBio Inc (IBRX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell IBRX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is IBRX’s price target for the next 12 months?
Analysts predict a range of price targets between $5.00 and $5.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for ImmunityBio Inc (IBRX) stock is $5.00.
